title: Maintenance therapy in epithelial ovarian cancer: from chemotherapy to targeted agents.
abstract: Over the past years, although no increase in the cure rate for advanced epithelial ovarian cancer patients has been achieved, a slow prolongation in patients survival has been observed, thanks to the introduction of effective second line or salvage therapies. Attempts to disease chronicization seem therefore of value in this setting. A major effort has been pursued to establish the role of maintenance therapies for epithelial ovarian cancer patients. Although chemotherapy does not seem to have an effective role, promising results are coming from trials investigating maintenance targeted treatments, especially with antiangiogenic agents or PARP inhibitors for selected patients. The aim of this article is to review current evidences on maintenance therapy for epithelial ovarian cancer and put the results in perspective.
authors: Division of Medical Oncology 2, Istituto Oncologico Veneto IRCCS, via Gattamelata 64, 35128, Padova, Italy.
authors: Cristina
authors: C
authors: Falci
authors: Maria Vittoria
authors: MV
authors: Dieci
authors: Valentina
authors: V
authors: Guarneri
authors: Caterina
authors: C
authors: Soldà
authors: Emilio
authors: E
authors: Bria
authors: Giampaolo
authors: G
authors: Tortora
authors: Pierfranco
authors: P
authors: Conte
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000077216:Carcinoma, Ovarian Epithelial; D005260:Female; D006801:Humans; D058990:Molecular Targeted Therapy; D009375:Neoplasms, Glandular and Epithelial / Q000188:drug therapy* / Q000473:pathology; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; D016879:Salvage Therapy / Q000379:methods; D015996:Survival Rate
chemical_list: D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D000067856:Poly(ADP-ribose) Polymerase Inhibitors
keywords: antiangiogenic agent; epithelial ovarian cancer; maintenance